🔴 Context Therapeutics is trading 8% down today after Q2 EPS miss and CT-95 discontinuation

Context Therapeutics is trading 8% down now at $0.45 after investors continued reassessing its August 5 second-quarter report.

• The company posted a $14.6 million net loss; reported EPS of -$0.15 missed the -$0.09 estimate.
• It discontinued CT-95 development to prioritize CTIM-76 and CT-202.
• The decline extends recent volatility following the August 6 27.27% selloff and August 7 close at $0.48; broader markets are only modestly lower, so company-specific earnings and pipeline concerns appear more relevant.